Table of Contents  
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 49-50  

A rare case modafinil dependence

1 Department of Psychiatry, Saveetha Medical College, Chennai, Tamil Nadu, India
2 Department of Pharmacology, Saveetha Medical College, Chennai, Tamil Nadu, India

Date of Submission24-Feb-2014
Date of Decision27-Jun-2014
Date of Acceptance28-Jun-2014
Date of Web Publication12-Jan-2015

Correspondence Address:
Krishnan Vengadaragava Chary
Department of Pharmacology, Saveetha Medical College, Chennai, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0976-500X.149149

Rights and Permissions

Modafinil, a non-amphetamine psychostimulant, is indicated for narcolepsy, shift work sleep disorder and severe obstructive sleep apnea syndrome. Modafinil is prescribed at the dose of 100 mg once in a day or as two doses, 12 h apart in a day. It has also been found that it reduces cocaine dependence and withdrawal phenomenon. Modafinil is claimed to have very low liability for abuse and dependence. Here we report a rare case of modafinil dependence.

Keywords: Drug dependence, modafinil, psychostimulant

How to cite this article:
Krishnan R, Chary KV. A rare case modafinil dependence. J Pharmacol Pharmacother 2015;6:49-50

How to cite this URL:
Krishnan R, Chary KV. A rare case modafinil dependence. J Pharmacol Pharmacother [serial online] 2015 [cited 2022 Jan 22];6:49-50. Available from:

   Case report Top

A 44 year old single male, presented to our outpatient department with complaints of day time excessive sleepiness, lethargy, low mood and disturbed sleep at night for the past 3 months. History revealed that these symptoms were triggered by the death of his father. On detailed evaluation, it was found that he had been on treatment for his mental illness from 2005. The course of illness was continuous characterized by withdrawn behavior, preoccupation, fear, auditory hallucinations, referential delusions and decline in social and occupational functioning. He was evaluated by a psychiatrist and started on psychotropics. During follow-up, the patient complained of episodes of depressed mood, anxiety and sleep disturbance, lethargy and sleepiness that affected his shift work, for which he was prescribed modafinil 200 mg, along with the antipsychotics Risperidone 4 mg and Amisulpride 400 mg. The patient himself gradually increased the dose to overcome the drowsiness that interrupted his shift work. He started with 100 mg every 3-4 h over a shift work of 12 h. For the last 6 months he was unable to overcome his sleepiness during work without modafinil 100 mg/h thus making a total of 1200 mg/day of modafinil which he used to obtain over the counter. He claimed to have symptoms of worsening of lethargy, tremors of hands, anxiety and erratic sleep hours when he skipped modafinil, patient reported a sense of well-being only with the drug and with the above dose.

There was no family history of mental illness. Physical examination was within normal limits except for fine tremors. His blood investigations gave the following values hemoglobin - 12.4 gm%;, WBC count - 6300 cells/mm 3 ; platelet count - 2.4 lakhs/mm 3 ;, random blood sugar - 122 mg/dl. His metabolic parameters including renal function, liver function, lipid profile were within normal limits. Electrocardiogram showed sinus rhythm and echocardiogram showed normal left ventricular function.

The provisional diagnosis made was schizoaffective disorder currently in partial remission. An additional diagnosis of modafinil dependence syndrome (dependence criteria as per DSM V) was made in view of the tolerance, withdrawal, inability to cut down, progressive increase in the amount of drug over a longer period of time and craving.

The dose was tapered slowly over a period of 1 month with 100 mg every 2-3 days and started on bupropion. He reported sleep disturbance, increased sense of body warmth, lethargy and low mood during the process of tapering the drug. Low dose of clonazepam was added to reduce the withdrawal symptoms. Patient reported significant improvement in his sleep pattern. His dysphoric mood and lethargy improved and his level of anhedonia and amotivation decreased.

   Discussion Top

In literature, only one case study has been reported on modafinil dependence at higher doses. In our case report, the patient reported himself started consuming more tablets to increase the effects derived from modafinil and landed with dependence phenomenon. [1]

Unlike amphetamine and its derivatives, Modafinil is said to act by mechanisms independent of dopminergic system which is involved in dependence phenomenon of sympathomimetics and opioids and hence is devoid of addiction potential. However there are few recent studies reporting that modafinil also binds to dopamine receptors and also affects dopamine uptake by dopamine transporters in the neurons. Increasing doses of modafinil was found to be a potent reinforcer. Another study conducted to know about modfinil's subjective and behavioral effects showed that modafinil increases rating scale of the Addiction Research Center Inventory (ARCI) as much as amphetamine. Modafinil dependence can be attributed to its dopamine uptake blockade thereby increasing its concentration in dopaminergic areas of brain. [2],[3] There is also a case of modafinil associated psychosis and reports of withdrawal phenomenon. [4] Overdose of modafinil is not safe; as a central nervous system stimulant it is prone to cause insomnia, agitation, tachycardia, rise in blood pressure etc. [5],[6],[7] There are no controlled trials or reports available for the treatment of Modafinil addiction. In this patient, we cross-tapered modafinil with bupropion because of its action on dopamine and norepinephrine reuptake inhibiton, thus producing an effect similar to that of modafinil with antidepressant activity.

Modafinil is listed as a schedule IV drug in the United States for its restricted sale. However in our country modafinil is available over the counter. There is no regulation on Modafinil sale which has to be revised to prevent its abuse. It is widely purchased over the counter by night shift workers to increase work the efficiency without sleep. Though abuse potential is claimed to be less, it should be considered serious due to increased use of modafinil among youngsters.

   Conclusion Top

Our case report is one among the very few reports of modafinil dependence, it gives a call for the need of regulations on the sale of modafinil.

   References Top

Kate N, Grover S, Ghormode D. Dependence on supratherapeutic doses of modafinil. A case report. Prim Care Companion CNS Disord 2012;14. pii: PCC.11l01333.  Back to cited text no. 1
Myrick H, Malcolm R, Taylor B, La Rowe S. Modafinil: Preclinical, clinical, and post-marketing surveillance-A review of abuse liability issues. Ann Clin Psychiatry 2004;16:101-9.  Back to cited text no. 2
Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 2009;301:1148-54.  Back to cited text no. 3
Marianni J, Hart CL. Pschosis associated with modafinil and shift work. Am J Psychiatry 2005;162:1983.  Back to cited text no. 4
Lackey GD, Alsop JA, Albertson TE. A 24 month retrospective study of adult modafinil ingestions. Clin Toxicol (Phila) 2007; 45:641.  Back to cited text no. 5
Carstairs SD, Urquhart A, Hoffman J, Clark RF, Cantrell FL. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol 2010;6:307-10.  Back to cited text no. 6
Spiller HA, Borys D, Griffith JR, Klein-Schwartz W, Aleguas A, Sollee D. Toxicity from modafinil ingestion. Clin Toxicol (Phila) 2009;47:153-6.  Back to cited text no. 7

This article has been cited by
1 Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder
Gianluigi Tanda, Melinda Hersey, Briana Hempel, Zheng-Xiong Xi, Amy Hauck Newman
Current Opinion in Pharmacology. 2021; 56: 13
[Pubmed] | [DOI]
2 Chronic modafinil administration to preadolescent rats impairs social play behavior and dopaminergic system
Valeska Cid-Jofré, Macarena Gárate-Pérez, Philip J. Clark, Viviana Valero-Jara, Rodrigo A. España, Ramón Sotomayor-Zárate, Gonzalo Cruz, Georgina M. Renard
Neuropharmacology. 2021; 183: 108404
[Pubmed] | [DOI]
3 A State-of-the-Art Review on the Use of Modafinil as A Performance-enhancing Drug in the Context of Military Operationality
Martine Van Puyvelde, Jeroen Van Cutsem, Emilie Lacroix, Nathalie Pattyn
Military Medicine. 2021;
[Pubmed] | [DOI]
4 Methamphetamine and sleep impairments: neurobehavioral correlates and molecular mechanisms
Monika Vrajová, Romana Šlamberová, Cyril Hoschl, Saak V Ovsepian
Sleep. 2021; 44(6)
[Pubmed] | [DOI]
5 Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Melinda Hersey, Amanda K. Bacon, Lydia G. Bailey, Mark A. Coggiano, Amy H. Newman, Lorenzo Leggio, Gianluigi Tanda
Frontiers in Neuroscience. 2021; 15
[Pubmed] | [DOI]
6 The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review
Safia Sharif, Amira Guirguis, Suzanne Fergus, Fabrizio Schifano
Brain Sciences. 2021; 11(3): 355
[Pubmed] | [DOI]
7 A review on modafinil: the characteristics, function, and use in critical care
Seyed MohammadReza Hashemian, Tayebeh Farhadi
Journal of Drug Assessment. 2020; 9(1): 82
[Pubmed] | [DOI]
8 Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions
Maddalena Mereu, Takato Hiranita, Chloe J. Jordan, Lauren E. Chun, Jessica P. Lopez, Mark A. Coggiano, Juliana C. Quarterman, Guo-Hua Bi, Jacqueline D. Keighron, Zheng-Xiong Xi, Amy Hauck Newman, Jonathan L. Katz, Gianluigi Tanda
Neuropsychopharmacology. 2020; 45(9): 1518
[Pubmed] | [DOI]
9 Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects
Ana Sousa, Ricardo Jorge Dinis-Oliveira
Substance Abuse. 2020; 41(2): 155
[Pubmed] | [DOI]
10 Effects of (R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell
Jacqueline D. Keighron, Juliana C. Quarterman, Jianjing Cao, Emily M. DeMarco, Mark A. Coggiano, Apre Gleaves, Rachel D. Slack, Claudio Zanettini, Amy Hauck Newman, Gianluigi Tanda
ACS Chemical Neuroscience. 2019; 10(4): 2012
[Pubmed] | [DOI]
11 In search of optimal psychoactivation: stimulants as cognitive performance enhancers
Emil Bartosz Rozenek, Monika Górska, Karolina Wilczynska, Napoleon Waszkiewicz
Archives of Industrial Hygiene and Toxicology. 2019; 70(3): 150
[Pubmed] | [DOI]
12 Modafinil Dependence: A Case with Attention-Deficit/Hyperactivity Disorder
Huseyin Alacam,Omer Basay,Selim Tumkaya,Mehmet Mart,Gokce Kar
Psychiatry Investigation. 2018; 15(4): 424
[Pubmed] | [DOI]
13 Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
Leigh C Walker,Andrew J Lawrence
Expert Opinion on Investigational Drugs. 2018; 27(8): 677
[Pubmed] | [DOI]
14 The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic
Hai-Ying Zhang,Guo-Hua Bi,Hong-Ju Yang,Yi He,Gilbert Xue,Jiajing Cao,Gianluigi Tanda,Eliot L Gardner,Amy Hauck Newman,Zheng-Xiong Xi
Neuropsychopharmacology. 2017;
[Pubmed] | [DOI]
15 An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Eric Murillo-Rodríguez,André Barciela Veras,Nuno Barbosa Rocha,Henning Budde,Sérgio Machado
ACS Chemical Neuroscience. 2017;
[Pubmed] | [DOI]
16 The unique psychostimulant profile of (±)-modafinil: investigation of behavioral and neurochemical effects in mice
Maddalena Mereu,Lauren E. Chun,Thomas E. Prisinzano,Amy H. Newman,Jonathan L. Katz,Gianluigi Tanda,Paul Bolam
European Journal of Neuroscience. 2016;
[Pubmed] | [DOI]
17 Modafinil Induces Rapid-Onset Behavioral Sensitization and Cross-Sensitization with Cocaine in Mice: Implications for the Addictive Potential of Modafinil
Raphael Wuo-Silva,Daniela F. Fukushiro,André W. Hollais,Renan Santos-Baldaia,Elisa Mári-Kawamoto,Laís F. Berro,Thaís S. Yokoyama,Leonardo B. Lopes-Silva,Carolina S. Bizerra,Roberta Procópio-Souza,Debora Hashiguchi,Lilian A. Figueiredo,Jose L. Costa,Roberto Frussa-Filho,Beatriz M. Longo
Frontiers in Pharmacology. 2016; 7
[Pubmed] | [DOI]
18 Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders
Andrew Krystal,Hrayr Attarian
Current Sleep Medicine Reports. 2016; 2(4): 218
[Pubmed] | [DOI]
19 Modafinil Dependence and Hypersexuality: A Case Report and Review of the Evidence
Sahoo Swapnajeet,Subodh BN,Gupta Gourav
Clinical Psychopharmacology and Neuroscience. 2016; 14(4): 402
[Pubmed] | [DOI]
20 Effects of Modafinil and R-Modafinil on Brain Stimulation Reward Thresholds: Implications for Their Use in the Treatment of Psychostimulant Dependence
Brian T. Burrows,Lucas R. Watterson,Meagan A. Johnson,M. Foster Olive
Journal of Drug and Alcohol Research. 2015; 4: 1
[Pubmed] | [DOI]
21 Modafinil
Reactions Weekly. 2015; 1540(1): 209
[Pubmed] | [DOI]
22 Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine
Michael Soyka,Jochen Mutschler
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015;
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Case report

 Article Access Statistics
    PDF Downloaded509    
    Comments [Add]    
    Cited by others 22    

Recommend this journal